Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics' stock price has experienced significant volatility. In November 2025, the company reported its third-quarter financial results and provided a corporate update. In December 2025, Aclaris Therapeutics was added to the Nasdaq Biotechnology Index (NBI). In January 2026, the company initiated a Phase 1b proof-of-concept trial in atopic dermatitis for ATI-052 and reported preclinical results showing ATI-2138 demonstrated rapid and sustained hair regrowth. In February 2026, analysts expressed concern over the company's high price-to-sales ratio, and Aclaris initiated a Phase 1b proof-of-concept trial in patients with asthma for its bispecific antibody ATI-052 and reported its fourth-quarter and full-year 2025 financial results. In March 2026, Aclaris Therapeutics completed enrollment in a Phase 2 trial of Bosakitug (ATI-045) in atopic dermatitis and announced a poster presentation on results from the Phase 2a trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting, where results provided additional support for the therapeutic potential of ATI-2138. In April 2026, Wall Street Zen downgraded Aclaris Therapeutics from a "hold" to a "sell" rating, while other analysts maintained "buy" or "outperform" ratings.

Traditional demand seasonality is not directly applicable to Aclaris Therapeutics' current pipeline of investigational drugs, as its products are primarily in clinical trials and not yet commercialized. The demand for its future commercialized products would likely be driven by disease prevalence, treatment efficacy, and market access rather than seasonal fluctuations.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for immuno-inflammatory diseases, utilizing its KINect® drug discovery platform and developing innovative biologic product candidates. The company operates through Therapeutics and Contract Research segments. Key product candidates include Bosakitug (ATI-045), ATI-2138, ATI-052, ATI-9494, Lepzacitinib (ATI-1777), and Zunsemetinib (ATI-450).

Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, United States, with primary operations and drug development focused in the United States. The company holds exclusive worldwide rights to ATI-052, excluding Greater China, and its subsidiaries include Aclaris Therapeutics International Limited (United Kingdom), Aclaris Life Sciences, Inc. (Delaware), and Confluence Discovery Technologies, Inc. (Delaware).

Aclaris Therapeutics' brand reputation is tied to its scientific advancements, clinical trial results, and investor confidence. The company has received a consensus "Strong Buy" or "Moderate Buy" rating from analysts, but was downgraded by Wall Street Zen in April 2026. Positive clinical data and inclusion in the Nasdaq Biotechnology Index have bolstered its scientific reputation and investor confidence, while an earnings miss could negatively influence investor sentiment.

Aclaris Therapeutics, Inc. has significant institutional ownership, with 125 institutional owners and shareholders holding 59% of the company. Major institutional owners include BML Capital Management, LLC, Vivo Capital, LLC, and BlackRock, Inc. The company's CEO, Neal Walker, directly holds 1.4% of the total shares outstanding, and individual insiders collectively own 2.26% of the company.